Company to discuss positive topline and additional clinical data for CY6463 in MELAS patients
Mitochondrial disease clinician-researcher, Amel Karaa, M.D., to discuss the potential future impact on patients
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Company to discuss positive topline and additional clinical data for CY6463 in MELAS patients
Mitochondrial disease clinician-researcher, Amel Karaa, M.D., to discuss the potential future impact on patients
Read more at globenewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| CYCN | 1.1700 | +0.0700 | +6.36% |
| Cyclerion Therapeutics Inc | |||